Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

6.785 -0.015 (-0.22%)
Streaming Delayed Price Updated: 3:10 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx Inc

< Previous 1 2 3 4 5 6 7 Next >
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Via AB Newswire
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S. 
From Ardelyx, Inc.
Via GlobeNewswire
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
From Ardelyx, Inc.
Via GlobeNewswire
Tenapanor for Hyperphosphatemia Approved in Japan
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.